V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214337 | 20129822 | 1.52 | 73 | Palliative (P) | 2019-08-27 | 2019-08-27 | IRINOTECAN + MDG + PANITUMUMAB | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100617183 |
| 20214338 | 20129823 | 1.68 | 86.2 | Palliative (P) | 2021-09-18 | 2021-10-16 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100085954 |
| 20214339 | 20129824 | 1.62 | 59.1 | null | 2016-05-07 | 2016-05-11 | Sorafenib | 02 | null | SORAFENIB | 101380360 |
| 20214342 | 20129825 | 1.82 | 54.8 | Palliative (P) | 2017-12-17 | 2019-03-02 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101693286 |
| 20214343 | 20129826 | 1.75 | 93.95 | Palliative (P) | 2020-01-30 | 2020-06-15 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101292578 |
| 20214346 | 20129827 | 1.84 | 57.2 | Palliative (P) | 2020-06-22 | 2020-08-08 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100824696 |
| 20214349 | 20129828 | 0 | 54 | Disease modification (D) | 2020-01-21 | 2020-03-21 | EOX | 02 | null | EOX | 101202817 |
| 20214350 | 20129829 | 1.71 | 74 | Palliative (P) | 2019-07-03 | 2019-07-03 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101540692 |
| 20214351 | 20129830 | 0 | 57.7 | Neo-adjuvant (N) | 2019-03-10 | 2019-03-13 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101169117 |
| 20214353 | 20129831 | 1.78 | 81 | null | 2016-06-12 | 2017-10-02 | Sorafenib | 02 | N | SORAFENIB | 101311220 |
| 20214357 | 20129832 | 1.68 | 88 | Disease modification (D) | 2017-07-04 | 2018-03-24 | EOX | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100501724 |
| 20214358 | 20129833 | 1.9 | 68.4 | null | 2020-02-26 | 2020-03-18 | Sorafenib | 01 | null | SORAFENIB | 101854727 |
| 20214360 | 20129834 | 1.78 | 86.6 | Adjuvant (A) | 2019-06-29 | 2019-07-16 | Sorafenib | 02 | Y | SORAFENIB | 101790358 |
| 20214361 | 20129835 | 1.84 | 78.5 | Neo-adjuvant (N) | 2018-06-09 | 2018-07-11 | EOX | N | N | EOX | 101585538 |
| 20214362 | 20129836 | 1.51 | 63.8 | null | null | 2018-03-25 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 101745274 |
| 20214363 | 20129837 | 1.51 | 73.5 | null | 2017-10-05 | 2018-06-02 | CAPECITABINE + RT | 02 | null | CAPECITABINE + RT | 101134149 |
| 20214364 | 20129838 | 1.85 | 40.4 | Palliative (P) | 2017-12-20 | 2017-12-23 | EOX | 02 | N | EOX | 101613455 |
| 20214366 | 20129839 | 1.72 | 91.25 | Palliative (P) | 2022-02-17 | 2022-02-25 | Sorafenib | 02 | N | SORAFENIB | 101259361 |
| 20214367 | 20129840 | 1.75 | 94 | Curative (C) | 2016-08-19 | 2016-09-07 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100259294 |
| 20214370 | 20129841 | 1.6 | 101.9 | Palliative (P) | 2020-01-06 | 2020-01-06 | Cetuximab + FLUOROURACIL + FOLINIC ACID + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100854982 |
| 20214372 | 20129842 | 1.59 | 59 | Palliative (P) | null | 2016-11-21 | EOX | 02 | N | CAPECITABINE + RT | 100718976 |
| 20214373 | 20129843 | 1.69 | 85.9 | Palliative (P) | null | 2020-05-10 | Cetuximab + FOLFIRI cycle 2 onwards | 01 | N | CETUXIMAB + IRINOTECAN + MDG | 100971146 |
| 20214374 | 20129844 | 1.89 | 57.5 | null | 2016-08-27 | 2016-12-01 | EOX | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100371394 |
| 20214375 | 20129845 | 1.75 | 60 | Palliative (P) | 2019-10-11 | 2019-11-21 | EOX | 02 | N | SORAFENIB | 100869684 |
| 20214376 | 20129846 | 1.65 | 64.8 | Palliative (P) | 2018-11-29 | 2018-12-06 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100706747 |
| 20214378 | 20129847 | 1.86 | 46.9 | Palliative (P) | 2017-06-29 | 2017-07-06 | Trial Unspecified | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100764959 |
| 20214379 | 20129848 | 1.62 | 75.3 | Palliative (P) | 2017-03-07 | 2017-03-15 | CETUXIMAB + IRINOTECAN + MDG | 02 | Y | CETUXIMAB + IRINOTECAN + MDG | 100449896 |
| 20214380 | 20129849 | 1.62 | 54 | Palliative (P) | 2019-04-27 | 2019-05-14 | Capecitabine 35days + RT | 02 | N | TRIAL | 101707416 |
| 20214382 | 20129850 | 1.56 | 82 | Palliative (P) | 2019-11-30 | 2019-12-02 | EOX | null | N | TRIAL | 100301551 |
| 20214383 | 20129851 | 1.72 | 86.2 | Palliative (P) | 2020-03-14 | 2020-05-24 | Trial Unspecified | 2 | null | TRIAL | 100238147 |
| 20214384 | 20129852 | 1.58 | 73.4 | Palliative (P) | 2020-04-07 | 2021-01-18 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101004453 |
| 20214388 | 20129853 | 1.78 | 58 | Adjuvant (A) | 2019-07-23 | 2019-08-06 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100756555 |
| 20214389 | 20129854 | 1.75 | 95.5 | Adjuvant (A) | 2019-10-29 | 2019-11-05 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 101274360 |
| 20214392 | 20129855 | 1.6 | 55.4 | Neo-adjuvant (N) | 2018-02-02 | 2018-02-17 | EOX | 02 | N | SORAFENIB | 100407029 |
| 20214393 | 20129856 | 1.83 | 71.2 | Palliative (P) | 2017-08-16 | 2018-01-02 | EOX | N | N | OXALIPLATIN + RALTITREXED | 100994666 |
| 20214394 | 20129857 | null | 127 | Adjuvant (A) | 2016-01-15 | 2016-05-03 | Sorafenib | N | N | SORAFENIB | 100897357 |
| 20214395 | 20129858 | 1.63 | 90 | Palliative (P) | 2018-09-16 | 2018-09-18 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 100069783 |
| 20214396 | 20129859 | 1.76 | 84.9 | Palliative (P) | 2016-05-30 | 2016-06-07 | EOX | N | Y | EOX | 101219015 |
| 20214397 | 20129860 | 1.73 | 111.7 | Palliative (P) | 2018-06-19 | 2018-07-18 | CAPECITABINE + RT | null | N | CAPECITABINE + RT | 100140643 |
| 20214398 | 20129861 | 1.66 | 65.4 | Adjuvant (A) | 2021-04-03 | 2021-05-07 | Cetuximab + FOLFIRI cycle1 | N | null | CETUXIMAB + IRINOTECAN + MDG | 101509617 |
| 20214399 | 20129862 | 1.66 | 62.2 | Curative (C) | null | 2016-09-25 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 2 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101069587 |
| 20214400 | 20129863 | 1.5 | 73.5 | Neo-adjuvant (N) | 2018-07-19 | 2018-09-28 | Trial Unspecified | N | N | TRIAL | 101129514 |
| 20214401 | 20129864 | 1.64 | 88 | Palliative (P) | 2019-06-22 | 2019-07-18 | EOX | 02 | null | SORAFENIB | 101188921 |
| 20214403 | 20129865 | 1.65 | 54 | Palliative (P) | 2019-09-16 | 2019-10-12 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 100968716 |
| 20214404 | 20129866 | 1.88 | 61 | Adjuvant (A) | 2018-06-06 | 2018-07-06 | Trial Unspecified | N | N | TRIAL | 101657638 |
| 20214405 | 20129867 | null | 94.4 | Adjuvant (A) | 2017-01-12 | 2017-05-08 | CAPECITABINE + RT | 02 | Y | CAPECITABINE + RT | 100813027 |
| 20214406 | 20129868 | 1.78 | 64.6 | null | 2017-01-30 | 2017-02-18 | EOX | Y | null | TRIAL | 101166960 |
| 20214409 | 20129869 | 1.63 | 79.6 | Adjuvant (A) | 2019-04-04 | 2019-04-04 | EOX | N | N | EOX | 100358330 |
| 20214410 | 20129870 | 1.66 | 83.1 | Palliative (P) | 2019-12-16 | 2020-01-03 | Cetuximab + FOLFIRI cycle 2 onwards | 01 | N | CETUXIMAB + IRINOTECAN + MDG | 100657953 |
| 20214411 | 20129871 | 1.74 | 75.4 | Palliative (P) | 2017-05-02 | 2017-05-28 | Capecitabine 42days + RT | 1 | Y | CAPECITABINE + RT | 100425643 |